A review and critique of studies reporting utility values for schizophrenia-related health states

PharmacoEconomics

Volumn 28, Issue 12, 2010, Pages 1109-1121

  Mavranezouli, Ifigeneia ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Patient preference; Quality of life; Schizophrenia; Social preference; Treatment; Utility measurement

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

BECK ANXIETY INVENTORY; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; EXTRAPYRAMIDAL SYMPTOM; HEALTH STATUS; HOSPITALIZATION; HUMAN; HYPERPROLACTINEMIA; METABOLIC SYNDROME X; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SHORT FORM 36; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNITED KINGDOM; VISUAL ANALOG SCALE; WEIGHT GAIN;

COST-BENEFIT ANALYSIS; HEALTH STATUS; HUMANS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SCHIZOPHRENIA;

EID: 78649313839     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11537300-000000000-00000     Document Type: Review

References (53)

1. National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd ed. London: NICE, 2008
2. Pharmaceutical Benefits Advisory Committee. 1995 Guidelines for the pharmaceutical industry on preparation of submission to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses. Barton (ACT): Australian Government, 1995 [online]. Available from URL:http://www.health.gov. au/internet/main/publishing.nsf/Content/health- pbsgeneral-pubs-pharmpac-part1.htm [Accessed 2009 Dec. 16]
3. Russell LB, Gold MR, Siegel JE, et al. The role of costeffectiveness analysis in health and medicine. JAMA 1996 Oct; 276(14):1172-7
4. Brazier J, Ratcliffe J, Salomon JA, et al. Measuring and valuing health benefits for economic evaluation. New York: Oxford University Press, 2007
5. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press, 2005
6. Brooks R. EuroQol: the current state of play. Health Policy 1996 Jul; 37(1):53-72
7. Gudex C, Dolan P, Kind P, et al. Health state valuations form the general public using the visual analogue scale. Qual Life Res 1996 Dec; 5(6):521-31
8. Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ 1996 Mar-Apr; 5(2):141-54
9. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 Nov; 35(11):1095-108
10. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008
11. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996 Oct; 276(15):1253-8
12. National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update). NICE clinical guideline 82. London: NICE, 2009 [online]. Available from URL:http://www.nice.org.uk/CG82 [Accessed 2010 Aug. 20]
13. National Collaborating Centre for Mental Health. Schizophrenia: the NICE guideline on the core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Updated ed. Leicester and London: The British Psychological Society and the Royal College of Psychiatrists, 2010
14. Centre for Reviews and Dissemination. NHS Economic Evaluation Database handbook. York: Centre for Reviews and Dissemination, University of York, 2007 [online]. Available from URL:http://www.york.ac.uk/inst/crd/pdf/nhseed-handb07. pdf [Accessed 2009 Oct. 20]
15. Cummins C, Stevens A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia: a West Midlands Development and Evaluation Committee report. Birmingham: University of Birmingham, Department of Public Health and Epidemiology, West Midlands Development and Evaluation Committee, 1998
16. Oh PI, Lanctôt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 2001;4(1-4): 137-56
17. Oh PI, Iskedjian M, Addis A, et al. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Can J Clin Pharmacol 2001 Winter; 8(4):199-206
18. Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997 Aug; 17(4):298-307
19. Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores [published erratum appears in Schizophr Res 2005 Dec. 1; 80(1):135-6]. Schizophr Res 2004 Nov. 1; 71(1):155-65
20. Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996 Jun; 11(2):101-8
21. Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008 Nov; 6:105
22. Rosser R, Cottee M, Rabin R, et al. Index of health-related quality of life. In: Hopkins A, editor. Measures of the quality of life and the uses to which such measures may be put. London: Royal College of Physicians, 1992:81-90
23. Barton GR, Hodgekins J, Mugford M, et al. Cognitive behaviour therapy for improving social recovery in psychosis: cost-effectiveness analysis. Schizophr Res 2009 Jul; 112 (1-3): 158-63
24. De Ridder A, De Graeve D. Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach. Pharmacoeconomics 2009;27(1):69-80
25. Knapp M, Windmeijer F, Brown J, et al. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics 2008;26(4):341-58
26. Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 2006 May; 10(17): iii-iv, ix-xi, 1-165
27. Lenert LA, Rupnow MFT, Elnitsky C. Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. Health Qual Life Outcomes 2005 Sep. 11; 3:57
28. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006 Dec; 163(12):2080-9
29. Gilbody SM, House AO, Sheldon TA. Outcome measurement in psychiatry: a critical review of outcomes measurement in psychiatric research and practice [NHS CRD report no. 23]. York: University of York, 2003 [online]. Available from URL:http://www.york.ac.uk/inst/crd/CRD-Reports/crdreport24.pdf [Accessed 2010 Mar. 5]
30. Jacobs R. Investigating patient outcome measures in mental health [CHE research paper no. 48]. York: University of York, 2009 [online]. Available from URL:http://www.york.ac.uk/inst/che/pdf/rp48.pdf [Accessed 2010 Mar. 5]
31. Prieto L, Sacristan JA, Hormaechea JA, et al. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 2004 Jun; 20(6):827-35
32. Konig HH, Roick C, Angermeyer MC. Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psychiatry 2007 Apr; 22(3):177-87
33. Barton GR, Hodgekins J, Mugford M, et al. Measuring the benefits of treatment for psychosis: validity and responsiveness of the EQ-5D. Br J Psychiatry 2009 Aug; 195(2):170-7
34. van de Willige G, Wiersma D, Nienhuis FJ, et al. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res 2005 Mar; 14(2):441-51
35. Meijer CJ, Schene AH, Koeter MWJ. Quality of life in schizophrenia measured by the MOS SF-36 and the Lancashire Quality of Life Profile. Acta Psychiatr Scand 2002 Apr; 105(4):293-300
36. Leese M, Schene A, Koeter M, et al. SF-36 scales, and simple sums of scales, were reliable quality-of-life summaries for patients with schizophrenia. J Clin Epidemiol 2008 Jun; 61(6):588-96
37. Brazier JE, Roberts J, Deverill M. The estimation of a preference based measure of health from the SF-36. J Health Econ 2002 Mar; 21(2):271-92
38. Brazier J. Measuring and valuing mental health for use in economic evaluation. J Health Serv Res Policy 2008 Oct; 13 Suppl. 3:70-5
39. McCrone P, Patel A, Knapp M, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ 2009 Mar; 12(1):27-31
40. Chisholm D, Healey A, Knapp M. QALYs and mental health care. Soc Psychiatry Psychiatr Epidemiol 1997 Feb; 32(2):68-75
41. Knapp M, Mangalore R. The trouble with QALYs Epidemiol Psichiatr Soc 2007 Oct-Dec; 16(4):289-93
42. Brazier J, Czoski-Murray C, Roberts J, et al. Estimation of a preference-based index from a condition-specific measure: the King's Health Questionnaire. Med Decis Making 2008 Feb; 28(1):113-26
43. Sundaram M, Smith MJ, Revicki DA, et al. Rasch analysis informed the development of a classification system for a diabetes-specific preference-based measure of health. J Clin Epidemiol 2009 Aug; 62(8):845-56
44. Yang Y, Brazier J, Tsuchiya A, et al. Estimating a preference-based single index from the Overactive Bladder Questionnaire. Value Health 2009 Jan; 12(1):159-66
45. Yang Y, Tsuchiya A, Brazier JE, et al. Estimating a preference-based single index from the Asthma Quality of Life Questionnaire (AQLQ) [Health Economics and Decision Science discussion paper no. 07/02]. Sheffield: School of Health and Related Research, 2007 [online]. Available from URL:http://www.shef. ac.uk/content/1/c6/01/87/47/HEDS%20DP%200702v2.pdf [Accessed 2009 Nov. 15]
46. Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999;3(9): i-iv, 1-164
47. Bebbington PE, Angermeyer M, Azorin JM, et al. Sideeffects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Sup 2009;119(438):22-8
48. Lee TT, Ziegler JK, Sommi R, et al. Comparison of preferences for health outcomes in schizophrenia among stakeholder groups. J Psychiatr Res 2000 May-Jun; 34(3):201-10
49. Lenert LA, Ziegler J, Lee T, et al. Differences in health values among patients, family members, and providers for outcomes in schizophrenia. Med Care 2000 Oct; 38(10):1011-21
50. Ubel PA, Loewenstein G, Jepson C. Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res 2003 Sep; 12(6):599-607
51. Shumway M. Preference weights for cost-outcome analyses of schizophrenia treatments: comparison of four stakeholder groups. Schizophr Bull 2003;29(2):257-66
52. Brazier J, Akehurst R, Brennan A, et al. Should patients have a greater role in valuing health states? Appl Health Econ Health Policy 2005;4(4):201-8
53. Voruganti L-NP, Awad AG, Oyewumi LK, et al. Assessing health utilities in schizophrenia: a feasibility study. Pharmacoeconomics 2000 Mar; 17(3):273-86